Compare RDW & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | TLX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2020 | 2024 |
| Metric | RDW | TLX |
|---|---|---|
| Price | $11.04 | $11.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $13.71 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 10.8M | 427.2K |
| Earning Date | 05-08-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,381,000.00 | N/A |
| Revenue This Year | $41.68 | N/A |
| Revenue Next Year | $20.25 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 10.29 | N/A |
| 52 Week Low | $4.87 | $6.28 |
| 52 Week High | $26.64 | $13.11 |
| Indicator | RDW | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 47.37 |
| Support Level | $9.99 | $10.92 |
| Resistance Level | $11.50 | $11.48 |
| Average True Range (ATR) | 0.67 | 0.40 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 45.43 | 24.90 |
Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.